125 related articles for article (PubMed ID: 29526407)
1. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
2. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double-negative T cells and newly generated T and B cells.
Haile Y; Adegoke A; Laribi B; Lin J; Anderson CC
Eur J Immunol; 2020 Sep; 50(9):1362-1373. PubMed ID: 32388861
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems.
Barbour M; Wood R; Harte T; Bushell TJ; Jiang HR
Immunology; 2022 Mar; 165(3):312-327. PubMed ID: 34826154
[TBL] [Abstract][Full Text] [Related]
6. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
Demir S; Pitarokoili K; Linker R; Gold R
J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
[TBL] [Abstract][Full Text] [Related]
7. Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype.
Milovanovic M; Volarevic V; Ljujic B; Radosavljevic G; Jovanovic I; Arsenijevic N; Lukic ML
PLoS One; 2012; 7(9):e45225. PubMed ID: 23028861
[TBL] [Abstract][Full Text] [Related]
8. Matrine downregulates IL-33/ST2 expression in the central nervous system of rats with experimental autoimmune encephalomyelitis.
Zhao X; Zhang X; Lv Y; Xu Y; Li M; Pan Q; Chu Y; Liu N; Zhang GX; Zhu L
Immunol Lett; 2016 Oct; 178():97-104. PubMed ID: 27562326
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice.
Chen H; Sun Y; Lai L; Wu H; Xiao Y; Ming B; Gao M; Zou H; Xiong P; Xu Y; Tan Z; Gong F; Zheng F
Neuroscience; 2015 Nov; 308():157-68. PubMed ID: 26363151
[TBL] [Abstract][Full Text] [Related]
10. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Li M; Li Y; Liu X; Gao X; Wang Y
J Neuroimmunol; 2012 Jun; 247(1-2):25-31. PubMed ID: 22516472
[TBL] [Abstract][Full Text] [Related]
11. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages.
Jiang HR; Milovanović M; Allan D; Niedbala W; Besnard AG; Fukada SY; Alves-Filho JC; Togbe D; Goodyear CS; Linington C; Xu D; Lukic ML; Liew FY
Eur J Immunol; 2012 Jul; 42(7):1804-14. PubMed ID: 22585447
[TBL] [Abstract][Full Text] [Related]
12. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells.
Xiao Y; Lai L; Chen H; Shi J; Zeng F; Li J; Feng H; Mao J; Zhang F; Wu N; Xu Y; Tan Z; Gong F; Zheng F
Mol Immunol; 2018 Sep; 101():550-563. PubMed ID: 30173119
[TBL] [Abstract][Full Text] [Related]
14. Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.
Souza PS; Gonçalves ED; Pedroso GS; Farias HR; Junqueira SC; Marcon R; Tuon T; Cola M; Silveira PCL; Santos AR; Calixto JB; Souza CT; de Pinho RA; Dutra RC
Mol Neurobiol; 2017 Aug; 54(6):4723-4737. PubMed ID: 27447807
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
17. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
18. CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.
Shafiei-Jahani P; Helou DG; Hurrell BP; Galle-Treger L; Howard E; Quach C; Painter JD; Fung M; Lo R; Allayee H; Akbari O
Mucosal Immunol; 2021 Jul; 14(4):899-911. PubMed ID: 33731828
[TBL] [Abstract][Full Text] [Related]
19. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses.
Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X
Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996
[TBL] [Abstract][Full Text] [Related]
20. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
